FDA Speaks About Sputnik V COVID-19 Vaccine Registration & Use in PH
SPUTNIK V – The Gamaleya Institute is planning to register the COVID-19 vaccine as a single-dose vaccine.
The COVID-19 pandemic remains to be a huge problem in front of many countries across the globe now. Several nations are in the pursuit of vaccinating a huge part of its citizens against the said coronavirus disease that is spreading for more than a year now.
Countries abide by a vaccination ladder that the prioritizes the healthcare workers. They are the frontliners in the fight against the pandemic. The senior citizens and those who have co-morbidities are also prioritized in the rolling out of the vaccines.
In the Philippines, before a brand of vaccine is rolled out, it seeks a permit from the Food and Drug Administration (FDA). One of the COVID-19 brands given by the FDA an “emergency use authorization” (EUA) is the Sputnik V.
Based on a report on ABS-CBN News, FDA Director-General Eric Domingo expressed that Gamaleya Institute informed them that they might make amendments on the EUA of the Sputnik V to lengthen the time interval between the two (2) doses.
“Parang very similar sa adenoviral vaccine natin na Astrazeneca, which we give in 12 weeks,” Domingo said.
Furthermore, according to the report, Gamaleya Institute is also planning to register Sputnik V as a single-dose vaccine like the Janssen vaccine. Domingo expressed that the FDA is currently waiting for the data that could support if it is “acceptable”.
With regards to the vaccines that is effective against the Delta variant which is the variant of concern now, studies show that Pfizer and AstraZeneca are effective against the said variant of COVID-19 that was first recorded in India. Pfizer was found to have 88% efficacy rate against Delta while AstraZeneca has 60%.
Thank you for visiting Philnews.ph. You may express your thoughts and reactions below through the comment section. You may also follow us on Facebook, on Twitter, and subscribe to our YouTube channel Philnews Ph.